Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Talaris Therapeutics, Inc. TALS
$2.66
-$0.08 (-3.10%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
129784806.00000000
-
week52high
9.47
-
week52low
0.89
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 ноя 2022 г. в 12:00
Описание компании
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Overweight | 05 июл 2022 г. |
| SVB Leerink | Market Perform | Outperform | 01 июл 2022 г. |
| Morgan Stanley | Overweight | Overweight | 24 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 23 мар 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 окт 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 20 окт 2022 г. |
| HC Wainwright & Co. | Buy | 20 окт 2022 г. | |
| HC Wainwright & Co. | Buy | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fenton Mary Kay | A | 150000 | 150000 | 01 февр 2023 г. |
| Fenton Mary Kay | A | 150000 | 150000 | 01 февр 2023 г. |
| Krieger Nancy | A | 120000 | 120000 | 01 февр 2023 г. |
| Krieger Nancy | A | 120000 | 120000 | 01 февр 2023 г. |
| Requadt Scott | A | 320000 | 320000 | 01 февр 2023 г. |
| Requadt Scott | A | 320000 | 320000 | 01 февр 2023 г. |
| Zdanowski Michael | A | 150000 | 150000 | 01 февр 2023 г. |
| Zdanowski Michael | A | 150000 | 150000 | 01 февр 2023 г. |
| Requadt Scott | A | 590193 | 4 | 30 дек 2022 г. |
| Zdanowski Michael | A | 121470 | 120000 | 10 сент 2022 г. |
Новостная лента
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Zacks Investment Research
21 окт 2022 г. в 12:48
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
Market Watch
20 окт 2022 г. в 08:24
Shares of Talaris Therapeutics Inc. TALS, -1.63% tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease.
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
GlobeNewsWire
04 окт 2022 г. в 07:00
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
GlobeNewsWire
21 сент 2022 г. в 07:00
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
06 сент 2022 г. в 07:00
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences: